Project Grant R01HL181098
Award Date 9/4/25
Completion Date 5/31/29
Dollars Obligated $744K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $131,571 to Vanderbilt University Medical Center to research methods for improving the trafficking of the KV11.1 potassium channel protein to treat Long QT Syndrome. The project aims to 1) test the drug candidate evacetrapib for its ability to enhance trafficking of KV11.1 variants, and 2) identify protein interactions that could...
- This federal Project Grant award, valued at $759,030.00 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the serotonin 2B receptor (5-HT2B) in degenerative mitral regurgitation and associated left ventricular remodeling. The research, to be conducted by Vanderbilt University from September 1, 2025 to May 31, 2029, aims to decouple the effects of 5-HT2B signaling on...
- The National Heart, Lung, and Blood Institute awarded a $171,488 project grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) under the Cardiovascular Diseases Research program (CFDA 93.837). The project aims to investigate the role of the protein CMYA5 in regulating the activity of the ryanodine receptor 2 (RYR2) in cardiomyocytes. Specifically, the research will examine how CMYA5 binds to and inhibits RYR2, which is involved in calcium signaling and...
- This Project Grant award of $634,183, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Loyola University of Chicago's Health Sciences Campus to investigate the molecular mechanisms of cardiac ryanodine receptor (RyR) dysfunction during oxidative stress and myocardial infarction. The primary goal is to define how oxidative stress-induced intersubunit cross-linking of RyR impacts calcium homeostasis and...
- This Project Grant award of $231,000.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), to study the functional impact of atrial myosin mutations associated with familial atrial arrhythmia. The research aims to comprehensively analyze the effects of known genetic mutations in the a-cardiac myosin heavy chain, essential light chain, and regulatory light chain on myosin activity and sarcomere...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,265 in funding to Weill Medical College of Cornell University from September 1, 2025 through June 30, 2029. The research project aims to expand understanding of how fibroblast growth factor homologous factors (FHFs) influence cardiac physiology and how genetic variants contribute to arrhythmias, providing a platform for targeted therapies. Key research objectives...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $673,598 to Baylor College of Medicine to conduct research on the role of cardiomyocyte-fibroblast signaling in atrial fibrillation (AF). The goal is to investigate how reduced production of the paracrine signaling molecule calcitonin, miR-31-dependent downregulation of the calcitonin receptor, and activated BMP1 signaling promote atrial remodeling, fibrosis, and AF...
- The Project Grant award titled "STRUCTURE, FUNCTION AND DRUG TREATMENT OF THE NATIVE CARDIAC SARCOMERE IN HYPERTROPHIC CARDIOMYOPATHY" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $149,804. The award aims to utilize advanced cryo-electron tomography (cryo-ET) imaging techniques to directly observe how hypertrophic cardiomyopathy (HCM)-causing mutations and the HCM drug mavacamten affect the structure and function of...
- This $125,703 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the role of the SYNE1-giant gene in atrial cardiomyopathy. The principal investigator is conducting a comprehensive study to understand the mechanisms by which mutations in the SYNE1 gene, which encodes mechanosensitive proteins in the nuclear envelope, contribute to the development of atrial fibrillation and sinus node dysfunction....
- This Project Grant award of $520,483 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The University of Texas Southwestern Medical Center to develop adeno-associated virus (AAV)-based gene therapy tools for efficient delivery of therapeutic cargos to the atrioventricular node (AVN) of the cardiac conduction system. The long-term goal is to devise new therapeutic approaches for cardiac dysrhythmias. The key objectives are to...